Listed drug firms likely to cut dividend payouts on worst profits

Published: 2013-02-21 06:59:00

Updated: 2013-02-21 06:59:00

Korean pharmaceutical listed firms are considering slashing their cash dividends to be paid out to their shareholders this year as most of their operating profits and net incomes tumbled by more than 10 percent last year due to the government’s forced cut in drug prices last April, data showed Tu...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK